A placental site nodule (PSN) is benign remnant from a previous pregnancy. Presentation
They are typically asymptomatic and found incidentally. Pathology
PSNs are intermediate trophoblastic remnants. Diagnosis
PSN are diagnosed by examining the tissue under a microscope, usually obtained with a dilation and curettage. Typically, they consist of pink (hyaline) material using the standard stain and contain few cells. Bizarre multinucleated cells may be present; however, there is no mitotic activity. The differential diagnosis includes (cervical) squamous cell carcinoma, gestational trophoblastic disease, and exaggerated placental site. Prognosis
PSN are benign. Once removed, they do not require any treatment and do not recur. See also
Gestational trophoblastic disease
Placental site trophoblastic tumour

References


== External links ==
mCPP is thought to be formed from nefazodone specifically by CYP2D6.The ratios of brain-to-plasma concentrations of mCPP to nefazodone are 47:1 in mice and 10:1 in rats, suggesting that brain exposure to mCPP may be much higher than plasma exposure. Conversely, hydroxynefazodone levels in the brain are 10% of those in plasma in rats. As such, in spite of its relatively low plasma concentrations, brain exposure to mCPP may be substantial, whereas that of hydroxynefazodone may be minimal. Chemistry
Nefazodone is a phenylpiperazine; it is an alpha-phenoxyl derivative of etoperidone which in turn was a derivative of trazodone. History
Nefazodone was discovered by scientists at Bristol-Myers Squibb (BMS) who were seeking to improve on trazodone by reducing its sedating qualities.BMS obtained marketing approvals worldwide for nefazodone in 1994. It was marketed in the US under the brand name Serzone and in Europe under the brand name Dutonin.In 2002 the FDA obligated BMS to add a black box warning about potential fatal liver toxicity to the drug label. Worldwide sales in 2002 were $409 million.In 2003 Public Citizen filed a citizen petition asking the FDA to withdraw the marketing authorization in the US, and in early 2004 the organization sued the FDA to attempt to force withdrawal of the drug. The FDA issued a response to the petition in June 2004 and filed a motion to dismiss, and Public Citizen withdrew the suit.Generic versions were introduced in the US in 2003 and Health Canada withdrew the marketing authorization that year.Sales of nefazodone were about $100 million in 2003.